Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bluejay Diagnostics, Inc.BJDX · Entity 8627 | Director | February 01, 2023 | February 16, 2023 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | Executive Vice Pres. & CFO | January 19, 2018 | January 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bluejay Diagnostics, Inc.
Report date February 01, 2023 · Filed February 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,500 |
Reported balance
After 2023-02-01 transaction · row 1
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 27,500 · Balance 27,500 |
SYNERGY PHARMACEUTICALS, INC.
Report date January 19, 2018 · Filed January 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2028-01-19 | Direct | 766,875 |
Reported balance
After 2018-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-19 · Grant · Acquired 82,500 · Balance 766,875 F1: 27,500 of the stock options vest on each of 1/19/2019, 2020 and 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 27,500 of the stock options vest on each of 1/19/2019, 2020 and 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 16, 2023 16:29 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantCommon Stock | 27,500 | $0.44 | $12,100.00 |
DisclosureSEC source: 0001213900-23-012462 · ownership.xml · nonDerivative · entry 1 Gemignani Gary G · CIK 0001512256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:16 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 2,500 | Not disclosed Strike: $1.26 | Not disclosed |
DisclosureSEC source: 0001213900-22-014604 · ownership.xml · derivative · entry 1 Gemignani Gary G · CIK 0001512256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 2,500 shares Expires 2032-03-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on December 15, 2022, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:00 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 25,000 | Not disclosed Strike: $2.72 | Not disclosed |
DisclosureSEC source: 0001213900-21-066040 · ownership.xml · derivative · entry 1 Gemignani Gary G · CIK 0001512256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-15 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the one-year anniversary of the date hereof, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:00 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 82,500 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-18-003610 · a4.xml · derivative · entry 1 Gemignani Gary G · CIK 0001512256 · Executive Vice Pres. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,875 Underlying: Common Stock · 82,500 shares Expires 2028-01-19 F1 · derivative.exercise_date: 27,500 of the stock options vest on each of 1/19/2019, 2020 and 2021. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 17:02 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 309,375 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-001495 · a4.xml · derivative · entry 1 Gemignani Gary G · CIK 0001512256 · Executive Vice Pres. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,375 Underlying: Common Stock · 309,375 shares Expires 2028-01-05 F1 · derivative.exercise_date: 103,125 of the stock options vest on each of 1/5/2019, 2020 and 2021. Read SEC document |
| May 01, 2017 Filed May 1, 2017 16:37 UTC | SYNERGY PHARMACEUTICALS, INC. SGYP · Entity 164269 | GrantStock Options · Derivative | 375,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001104659-17-028423 · a4.xml · derivative · entry 1 Gemignani Gary G · CIK 0001512256 · Executive Vice Pres. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2027-05-01 F1 · derivative.exercise_date: 125,000 of the stock options vest on each of 4/17/2018, 2019 and 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.